Supplementary Table. Adjusted Odds of Medication Use or Behavioral Therapy in Patients with Peripheral Artery Disease Seeing Physicians in U.S. Ambulatory Care Visits, 2006-2013

Characteristics	Antiplatelet Adj. OR (95% CI)	P value	Cilostazol Adj. OR (95% CI)	P value	Statin Adj. OR (95% CI)	P value	ACE inhibitor/ARB Adj. OR (95% CI)	P value
Sex								
Men	1.0		1.0		1.0		1.0	
Female	1.0 (0.7- 1.4)	0.89	0.6 (0.3- 1.2)	0.17	0.8 (0.5- 1.1)	0.12	0.7 (0.5- 1.0)	0.06
Race/ethnicity								
White	1.0		1.0		1.0		1.0	
Non-White	1.5 (0.9- 2.5)	0.13	1.9 (0.5- 6.4)	0.33	1.0 (0.6- 1.8)	0.98	1.4 (0.8- 2.4)	0.27
Age								
<65	1.0		1.0		1.0		1.0	
≥65	1.3 (0.8- 1.9)	0.26	0.6 (0.2- 1.4)	0.24	1.7 (1.0- 2.7)	0.04	1.0 (0.7- 1.5)	0.99
Insurance								
Private								
Non-private insurance	1.2 (0.8- 1.8)	0.47	1.4 (0.6- 3.4)	0.41	0.8 (0.5- 1.2)	0.27	1.1 (0.7- 1.8)	0.75
Urban or rural setting								
Urban	1.0		1.0		1.0		1.0	
Rural	0.9 (0.6- 1.5)	0.70	2.0 (0.8- 5.1)	0.15	0.5 (0.3- 1.0)	0.04	0.5 (0.3- 1.0)	0.04
Risk Factor History								
Obesity	0.8 (0.4- 1.3)	0.33			0.8 (0.4- 1.3)	0.34	1.1 (0.6- 2.0)	0.73
Smoker	1.4 (0.9- 2.2)	0.16			1.1 (0.7- 1.8)	0.65	1.0 (0.7- 1.5)	0.99
COPD	0.7 (0.4- 1.3)	0.32			1.3 (0.8- 2.2)	0.33	1.1 (0.6- 1.8)	0.80
Dyslipidemia	1.3 (0.8- 2.0)	0.27			3.3 (2.2- 5.1)	<0.001	1.6 (1.1- 2.4)	0.03
Diabetes	0.9 (0.6- 1.4)	0.60			1.2 (0.8- 2.0)	0.37	1.6 (1.1- 2.5)	0.02
Hypertension	1.2 (0.9- 1.7)	0.21			1.2 (0.8- 1.8)	0.40	1.9 (1.2- 3.0)	<0.01
Chronic kidney disease	1.4 (0.7- 2.8)	0.31			0.7 (0.4- 1.5)	0.41	0.7 (0.3- 1.7)	0.45
Comorbid cardiovascular diseases								
Coronary artery disease	2.3 (1.6- 3.4)	<0.001	1.0 (0.5- 2.1)	0.91	1.6 (1.0- 2.4)	0.04	1.2 (0.9- 1.8)	0.27
Stroke	1.0 (0.6- 1.7)	0.93	1.0 (1.0- 1.0)	.	1.4 (0.8- 2.4)	0.20	1.2 (0.7- 2.1)	0.45
Time trend	1.0 (0.9- 1.1)	0.62	1.0 (0.9- 1.2)	0.91	1.0 (0.9- 1.1)	0.57	0.9 (0.9- 1.0)	0.16

Characteristics	Exercise or Diet Counseling			Smoking Cessation Advice or Medications*			
	Adj. OR (95% CI)		P value	Adj. OR (95% CI)			P value
Sex							
Men	1.0			1.0			
Female	1.2	(0.7- 2.0)	0.49	1.1	(0.5-	2.1)	0.88
Race/ethnicity							
White	1.0			1.0			
Non-White	1.3	(0.6- 2.7)	0.47	0.3	(0.1-	0.9)	0.03
Age							
<65	1.0			1.0			
≥65	0.7	(0.4- 1.2)	0.18	0.3	(0.1-	0.7)	<0.01
Insurance							
Private							
Non-private insurance	0.8	(0.4- 1.7)	0.63	1.0	(0.5-	2.1)	0.98
Urban or rural setting							
Urban	1.0			1.0			
Rural	0.6	(0.3- 1.1)	0.10	0.8	(0.3-	2.6)	0.77
Risk Factor History							
Obesity	3.5	(2.1- 6.1)	<0.001	0.8	(0.3-	2.2)	0.64
Smoker	0.8	(0.5- 1.5)	0.55				
COPD	0.5	(1.3- 0.8)	2.18	1.4	(0.6-	3.2)	0.47
Dyslipidemia	1.8	(1.1- 3.0)	0.03	1.6	(0.8-	3.4)	0.18
Diabetes	1.1	(0.7- 1.7)	0.84	1.0	(0.5-	1.9)	0.88
Hypertension	1.6	(0.9- 2.7)	0.09	0.7	(0.3-	1.7)	0.42
Chronic kidney disease	1.2	(0.5- 2.8)	0.68	1.5	(0.4-	5.3)	0.52
Comorbid cardiovascular diseases							
Coronary artery disease	0.9	(0.5- 1.6)	0.71	3.5	(1.6-	7.4)	<0.01
Stroke	1.3	(0.7- 2.3)	0.38	0.6	(0.2-	2.1)	0.42
Time trend	0.9	(0.8- 1.0)	0.10	1.0	(0.9-	1.2)	0.69

Abbreviations: PAD, peripheral artery disease; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease

Notes: Trend analyses based on logistic regression models using 2005-2012 data, with adjustment for patient characteristics. Regression model for cilostazol includes a limited number of covariates due to sample size restrictions.

*Medications for smoking cessation include nicotine replacement therapy, varenicline, and bupropion